ReviewAnnals of intensive care2020
Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review.
Review in Annals of intensive care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it, 219 citations in OpenAlex.
- Are Pre-Hospitalization ECG Abnormalities Associated With Increased Mortality in COVID-19 Patients? A Quantitative Systematic Literature Review.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024Pooled it
- Pooled it
- Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action.Journal of cardiovascular translational research · 2022Pooled it
- COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies.Frontiers in cardiovascular medicine · 2020Pooled it
- Influenza A vs. COVID-19: A Retrospective Comparison of Hospitalized Patients in a Post-Pandemic Setting.Microorganisms · 2025Article
- Prevalence of thromboembolic events in critically-ill COVID-19 patients infected with Omicron: results from the French prospective, multicenter SEVARVIR cohort study.Critical care (London, England) · 2025Article
- Associations between metabolomic scores and clinical outcomes in hospitalized COVID-19 patients.GeroScience · 2025Article
- Review
- Recurrent, Acute Limb Ischemia Secondary to Arterial Thrombosis: A Devastating Complication in the Setting of Severe COVID-19 Infection.HCA healthcare journal of medicine · 2025Article
- Thromboelastography in COVID-19 patients: An observational study in the South African context.African journal of laboratory medicine · 2025Article
- The Impact of MELD, PESI, PSI, and DIC Scores on Predicting Pulmonary Thromboembolism and Mortality Rate in COVID-19 Pneumonia.Tanaffos · 2025Article
- Efficient management of pulmonary embolism diagnosis using a two-step interconnected machine learning model based on electronic health records data.Health information science and systems · 2024Article
- COVID-19 Coagulopathy.Life (Basel, Switzerland) · 2024Review
- High prevalence of cardiac post-acute sequelae in patients recovered from Covid-19. Results from the ARCA post-COVID study.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- The emerging role of heart-on-a-chip systems in delineating mechanisms of SARS-CoV-2-induced cardiac dysfunction.Bioengineering & translational medicine · 2024Review
- Risk Factors for Pulmonary Embolism in Individuals Infected with SARS-CoV2-A Single-Centre Retrospective Study.Biomedicines · 2024Article
- Venous Thromboembolism and Associated Factors in Hospitalized Patients with COVID-19 at Addis Ababa COVID-19 Field Hospital, Ethiopia.Infection and drug resistance · 2024Article
- Article
- Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era.Acta pharmacologica Sinica · 2023Review
- Simple demographic, laboratory and chest radiograph variables can identify COVID-19 patients with pulmonary thromboembolism: a retrospective multicentre United Kingdom study.The British journal of radiology · 2023Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreliminary reports have described significant procoagulant events in patients with coronavirus disease-2019 (COVID-19), including life-threatening pulmonary embolism (PE). MAIN TEXT: We review the current data on the epidemiology, the possible underlying pathophysiologic mechanisms, and the therapeutic implications of PE in relation to COVID-19. The incidence of PE is reported to be around 2.6-8.9% of COVID-19 in hospitalized patients and up to one-third of those requiring intensive care unit (ICU) admission, despite standard prophylactic anticoagulation. This may be explained by direct and indirect pathologic consequences of COVID-19, complement activation, cytokine release, endothelial dysfunction, and interactions between different types of blood cells.
conclusionThromboprophylaxis should be started in all patients with suspected or confirmed COVID-19 admitted to the hospital. The use of an intermediate therapeutic dose of low molecular weight (LMWH) or unfractionated heparin can be considered on an individual basis in patients with multiple risk factors for venous thromboembolism, including critically ill patients admitted to the ICU. Decisions about extending prophylaxis with LMWH after hospital discharge should be made after balancing the reduced risk of venous thromboembolism (VTE) with the risk of increased bleeding events and should be continued for 7-14 days after hospital discharge or in the pre-hospital phase in case of pre-existing or persisting VTE risk factors. Therapeutic anticoagulation is the cornerstone in the management of patients with PE. Selection of an appropriate agent and correct dosing requires consideration of underlying comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.